<DOC>
	<DOC>NCT02573610</DOC>
	<brief_summary>The purpose of this study is to evaluate superior efficacy of DE-108 ophthalmic solution to that of Levofloxacin 0.5% ophthalmic solution as well as safety of the former used for perioperative bacteria eradication in patients who are scheduled for cataract surgery.</brief_summary>
	<brief_title>Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Those who are scheduled for cataract surgery Those who with suspected ocular infections based on clinical findings in the study eye. Those who have any eye disease other than cataract which requires treatment in the target eye. Those who have a history of allergy to the drugs to be used during the clinical study (such as fluoroquinolones, topical anesthetics and povidon iodine) Those who need to wear contact lenses during the study period</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>